Jefferies Global Healthcare Conference
Logotype for Monte Rosa Therapeutic Inc

Monte Rosa Therapeutic (GLUE) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Monte Rosa Therapeutic Inc

Jefferies Global Healthcare Conference summary

17 Nov, 2026

Molecular glue platform

  • True small-molecule degraders bind ubiquitin ligases and reshape their surface to create a new protein-protein interaction, enabling selective protein removal; selectivity is intended to support safety.

  • The approach is being applied across multiple disease areas.

MRT-8102 and indication strategy

  • MRT-8102 targets the NLRP3 inflammasome in sterile inflammation linked to intrinsic metabolites; prioritized indications are gout, ASCVD and hidradenitis suppurativa (HS).

  • Gout was viewed as potentially the lowest-risk indication, supported by clinical and preclinical validation; ASCVD remains a focus despite the ZEUS trial outcome, while HS carries risk from placebo overperformance in the field.

  • Management attributed ZEUS limitations to IL-6 inhibition leaving ~20%-25% of IL-6 active and trial-design issues, including comorbidities; the ASCVD program will target the pathway further upstream and use a different design.

Gout phase II

  • GEMINI-1 is a small, two-dose study with an open-label expansion; frequent-flare patients start therapy during an acute flare, with prevention of subsequent flares as the key outcome.

  • The trial was on track to initiate in Q4 2026, with a data readout guided for H2 2027; management expressed confidence in timely recruitment.

  • Historical untreated flare rates are 50%-60% over 3-6 months; cutting that rate in half was described as a meaningful benchmark, subject to the recruited population and its characteristics.

  • The study will not use placebo control; historical data and prior IL-1β antibody results were cited as context for interpreting flare reduction.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Monte Rosa Therapeutic